

# **Vaccine Adjuvants Market by Product Type (Particulate, Emulsions, Pathogen, Saponin), Route of Administration (Subcutaneous, Intramuscular), Disease Type (Infectious, Cancer), Application (Research, Commercial) & Application Category - Forecasts to 2021**

<https://marketpublishers.com/r/V8A666B7FDBEN.html>

Date: June 2016

Pages: 159

Price: US\$ 5,650.00 (Single User License)

ID: V8A666B7FDBEN

## **Abstracts**

The vaccine adjuvants market is expected to reach USD 769.4 million by 2021 from USD 467.0 million in 2016, at a CAGR of 10.5%. The global vaccine adjuvants market is segmented based on product type, route of administration, disease type, applications, and application categories.

On the basis of type, the vaccine adjuvants market is segmented into pathogen components, adjuvant emulsions, particulate adjuvants, combination adjuvants, and others. The particulate adjuvants segment is expected to account for the largest share of the global vaccine adjuvants market in 2016. Growth in this segment can primarily be attributed to increasing investments in research.

On the basis of route of administration, the market is segmented into subcutaneous, intranasal, intramuscular, intradermal, and others. The intramuscular segment is expected to account for the largest share of the global vaccine adjuvants market in 2016. Increasing prevalence of diseases and the need for new vaccine adjuvants with better efficacy will drive the growth of this market.

Geographically, the vaccine adjuvants market is dominated by North America, followed by Europe, Asia, and the Rest of the World (RoW). Growth in the North American segment is primarily driven by the rapidly increasing aging population and rising

government funding in the North American countries.

The major factors contributing to the growth of the vaccine adjuvants market include increasing government funding for research, high prevalence of diseases, expanding biotechnology and biopharmaceutical industries, and growing focus on improved vaccination. Furthermore, increasing R&D spending as well as acquisitions, collaborations, and agreements by companies is another major factor driving the growth of this market.

Apart from comprehensive geographic and product analysis and market sizing, the report also provides a competitive landscape that covers the growth strategies adopted by industry players over the last three years. In addition, the company profiles comprise the product portfolios, developments, and strategies adopted by the market players to maintain and increase their shares in the market. The above-mentioned market research data, current market size, and forecast of the future trends will help key market players and new entrants to make the necessary decisions regarding product offerings, geographic focus, change in strategic approach, and levels of output in order to remain successful in the market.

The major players in the vaccine adjuvants market are Brenntag Biosector (Denmark), CSL Limited (Australia), SEPPIC (France), Agenus, Inc. (U.S.), Novavax, Inc. (U.S.), SPI Pharma, Inc. (U.S.), Invivogen (U.S.), Avanti Polar Lipids, Inc. (U.S.), MPV Technologies (U.S.), and OZ Biosciences (France).

Reasons to Buy the Report:

This report will enable both established firms as well as new entrants/smaller firms to gauge the pulse of the market, which in turn will help these firms garner greater market shares. Firms purchasing the report can use any one or a combination of the below-mentioned five strategies (market penetration, product development/innovation, market development, market diversification, and competitive assessment) for strengthening their market shares.

The report provides insights on the following pointers:

**Market Penetration:** Comprehensive information on the product portfolios of the top players in the vaccine adjuvants market. The report analyzes the vaccine adjuvants market by type, route of administration, disease type, applications, and target group

**Product Development/Innovation:** Detailed insights on the upcoming technologies, R&D activities, and new product launches in the vaccine adjuvants market

**Competitive Assessment:** In-depth assessment of the market strategies, geographic and business segments, and product portfolios of the leading players in the vaccine adjuvants market

**Market Development:** Comprehensive information about emerging markets. This report analyzes the market for various vaccine adjuvants across geographies

**Market Diversification:** Exhaustive information about new products, untapped geographies, recent developments, and investments in the vaccine adjuvants market

## Contents

### **1 INTRODUCTION**

- 1.1 OBJECTIVES OF THE STUDY
- 1.2 MARKET DEFINITION
- 1.3 MARKET SCOPE
  - 1.3.1 MARKET SEGMENTATION
  - 1.3.2 MARKETS COVERED
  - 1.3.3 YEARS CONSIDERED FOR THE STUDY
- 1.4 CURRENCY
- 1.5 LIMITATIONS
- 1.6 MARKET STAKEHOLDERS

### **2 RESEARCH METHODOLOGY**

- 2.1 KEY INDICATORS
  - 2.1.1 INTRODUCTION
  - 2.1.2 MACROINDICATORS
    - 2.1.2.1 Rapid growth of aging population
    - 2.1.2.2 Incidence and prevalence of cancer
    - 2.1.2.3 Burden of infectious diseases
    - 2.1.2.4 Healthcare expenditure patterns
- 2.2 MARKET SIZE ESTIMATION
- 2.3 MARKET BREAKDOWN AND DATA TRIANGULATION
- 2.4 KEY DATA FROM SECONDARY SOURCES
- 2.5 KEY DATA FROM PRIMARY SOURCES
- 2.6 KEY INDUSTRY INSIGHTS
- 2.7 ASSUMPTIONS FOR THE STUDY

### **3 EXECUTIVE SUMMARY**

- 3.1 INTRODUCTION
- 3.2 CURRENT SCENARIO
- 3.3 FUTURE OUTLOOK
- 3.4 CONCLUSION

### **4 PREMIUM INSIGHTS**

- 4.1 VACCINE ADJUVANTS MARKET OVERVIEW
- 4.2 VACCINE ADJUVANTS MARKET, BY APPLICATION
- 4.3 GEOGRAPHICAL SNAPSHOT OF THE VACCINE ADJUVANTS MARKET
- 4.4 GEOGRAPHIC ANALYSIS: VACCINE ADJUVANTS MARKET, BY APPLICATION CATEGORY
- 4.5 GEOGRAPHIC ANALYSIS: VACCINE ADJUVANTS MARKET, BY DISEASE TYPE
- 4.6 LIFECYCLE ANALYSIS, BY REGION, 2015

## **5 MARKET OVERVIEW**

### 5.1 INTRODUCTION

### 5.2 MARKET DYNAMICS

#### 5.2.1 DRIVERS

- 5.2.1.1 Increasing use of adjuvants in vaccine
- 5.2.1.2 High prevalence of infectious and zoonotic diseases
- 5.2.1.3 Increase in livestock and instances of diseases
- 5.2.1.4 Increasing focus on immunization programs from various government bodies
- 5.2.1.5 Technological advancements in aluminum hydroxide-based adjuvants
- 5.2.1.6 Increasing focus and support on the discovery and development of vaccine

adjuvants

- 5.2.1.7 Increasing geriatric population

#### 5.2.2 RESTRAINTS

- 5.2.2.1 High cost of adjuvant research
- 5.2.2.2 Stringent regulatory environment and time-consuming approvals

#### 5.2.3 OPPORTUNITIES

- 5.2.3.1 Combination adjuvants
- 5.2.3.2 Pandemic diseases

#### 5.2.4 CHALLENGES

- 5.2.4.1 Identification of adjuvants

#### 5.2.5 TRENDS

- 5.2.5.1 Collaborations

### 5.3 KEY PIPELINE PRODUCTS

### 5.4 REGULATORY LANDSCAPE

#### 5.4.1 NORTH AMERICA

#### 5.4.2 EUROPE

- 5.4.2.1 Manufacturing specifications
- 5.4.2.2 Routine testing
- 5.4.2.3 Stability

#### 5.4.3 ASIA

#### 5.4.4 ROW

### **6 GLOBAL VACCINE ADJUVANTS MARKET, BY PRODUCT TYPE**

- 6.1 INTRODUCTION
- 6.2 PARTICULATE ADJUVANTS
- 6.3 ADJUVANT EMULSIONS
- 6.4 PATHOGEN COMPONENTS
- 6.5 COMBINATION ADJUVANTS
- 6.6 OTHERS

### **7 GLOBAL VACCINE ADJUVANTS MARKET, BY ROUTE OF ADMINISTRATION**

- 7.1 INTRODUCTION
- 7.2 INTRAMUSCULAR ROUTE
- 7.3 SUBCUTANEOUS ROUTE
- 7.4 INTRANASAL ROUTE
- 7.5 ORAL ROUTE
- 7.6 INTRADERMAL ROUTE
- 7.7 OTHERS

### **8 GLOBAL VACCINE ADJUVANT MARKET, BY DISEASE TYPE**

- 8.1 INTRODUCTION
- 8.2 INFECTIOUS DISEASES
- 8.3 CANCER
- 8.4 OTHERS

### **9 GLOBAL VACCINE ADJUVANTS MARKET, BY APPLICATION**

- 9.1 INTRODUCTION
- 9.2 RESEARCH APPLICATION
- 9.3 COMMERCIAL APPLICATION

### **10 GLOBAL VACCINE ADJUVANTS MARKET, BY APPLICATION CATEGORY**

- 10.1 INTRODUCTION
- 10.2 HUMAN VACCINE ADJUVANTS
- 10.3 VETERINARY VACCINE ADJUVANTS

## **11 GLOBAL VACCINE ADJUVANTS MARKET, BY REGION**

### 11.1 INTRODUCTION

### 11.2 NORTH AMERICA

#### 11.2.1 U.S.

#### 11.2.2 CANADA

### 11.3 EUROPE

#### 11.3.1 GERMANY

#### 11.3.2 U.K.

#### 11.3.3 FRANCE

#### 11.3.4 REST OF EUROPE

### 11.4 ASIA

#### 11.4.1 CHINA

#### 11.4.2 INDIA

#### 11.4.3 REST OF ASIA

### 11.5 REST OF THE WORLD

## **12 COMPETITIVE LANDSCAPE**

### 12.1 OVERVIEW

### 12.2 MARKET SHARE ANALYSIS

### 12.3 COMPETITIVE SITUATION AND TRENDS

#### 12.3.1 AGREEMENTS & COLLABORATIONS

#### 12.3.2 ACQUISITIONS

#### 12.3.3 EXPANSIONS

#### 12.3.4 OTHERS

## **13 COMPANY PROFILE**

(Introduction, Products & Services, Strategy, & Analyst Insights, Developments, MnM View)\*

### 13.1 INTRODUCTION

### 13.2 BRENNTAG BIOSECTOR A/S (A SUBSIDIARY OF BRENNTAG AG)

### 13.3 SEPPIC (A SUBSIDIARY OF AIR LIQUIDE GROUP)

### 13.4 CSL LIMITED

### 13.5 AGENUS, INC.

### 13.6 NOVAVAX, INC.

13.7 INVIVOGEN

13.8 SPI PHARMA, INC. (A SUBSIDIARY OF ASSOCIATED BRITISH FOODS PLC.)

13.9 AVANTI POLAR LIPIDS, INC.

13.10 MVP LABORATORIES INC.

13.11 OZ BIOSCIENCES

\*Details on MarketsandMarkets view, Introduction, Product & Services, Strategy, & Analyst Insights, New Developments might not be captured in case of unlisted companies.

## **14 APPENDIX**

14.1 INSIGHTS OF INDUSTRY EXPERTS

14.2 DISCUSSION GUIDE

14.3 KNOWLEDGE STORE: MARKETSandMARKETS' SUBSCRIPTION PORTAL

14.4 AVAILABLE CUSTOMIZATIONS

14.5 INTRODUCING RT: REAL-TIME MARKET INTELLIGENCE

14.6 RELATED REPORTS



## List Of Tables

### LIST OF TABLES

Table 1 INCREASING USE OF ADJUVANTS IN VACCINE-PREVENTABLE DISEASES DRIVES THE MARKET GROWTH

Table 2 HIGH COST OF ADJUVANT RESEARCH RESTRAINTS THE MARKET GROWTH

Table 3 COMBINED ADJUVANTS AND PANDEMIC DISEASES OFFER GROWTH OPPORTUNITIES FOR MARKET PLAYERS

Table 4 IDENTIFICATION OF ADJUVANTS CHALLENGES THE GROWTH OF THIS MARKET

Table 5 COLLABORATIONS OFFER GROWTH TRENDS FOR MARKET PLAYERS

Table 6 FDA APPROVED VACCINE ADJUVANTS

Table 7 LICENSED VACCINES CONTAINING ADJUVANTS

Table 8 EXAMPLES OF VACCINE ADJUVANTS IN CLINICAL TRIALS

Table 9 VACCINE ADJUVANTS MARKET SIZE, BY PRODUCT TYPE, 2014–2021

Table 10 LIST OF PARTICULATE ADJUVANTS APPROVED FOR HUMAN USE (2015)

Table 11 PARTICULATE ADJUVANTS MARKET SIZE, BY REGION, 2014–2021(USD MILLION)

Table 12 NORTH AMERICA PARTICULATE ADJUVANTS MARKET SIZE, BY COUNTRY, 2014–2021(USD MILLION)

Table 13 EUROPE PARTICULATE ADJUVANTS MARKET SIZE, BY COUNTRY, 2014–2021(USD MILLION)

Table 14 ASIA PARTICULATE ADJUVANTS MARKET SIZE, BY COUNTRY, 2014–2021(USD MILLION)

Table 15 LIST OF ADJUVANT EMULSIONS APPROVED FOR HUMAN USE (2015)

Table 16 ADJUVANTS EMULSION MARKET SIZE, BY REGION, 2014–2021(USD MILLION)

Table 17 NORTH AMERICA ADJUVANT EMULSIONS MARKET SIZE, BY COUNTRY, 2014–2021(USD MILLION)

Table 18 EUROPE ADJUVANT EMULSIONS MARKET SIZE, BY COUNTRY, 2014–2021(USD MILLION)

Table 19 ASIA ADJUVANT EMULSIONS MARKET SIZE, BY COUNTRY, 2014–2021(USD MILLION)

Table 20 PATHOGEN COMPONENTS AND ITS DESCRIPTION

Table 21 PATHOGEN COMPONENTS MARKET SIZE, BY REGION, 2014–2021(USD MILLION)

Table 22 NORTH AMERICA PATHOGEN COMPONENTS MARKET SIZE, BY COUNTRY, 2014–2021(USD MILLION)

Table 23 EUROPE PATHOGEN COMPONENTS MARKET SIZE, BY COUNTRY, 2014–2021(USD MILLION)

Table 24 ASIA PATHOGEN COMPONENTS MARKET SIZE, BY COUNTRY, 2014–2021(USD MILLION)

Table 25 LIST OF COMBINATION ADJUVANT APPROVED FOR HUMAN USE (2015)

Table 26 COMBINATION ADJUVANTS MARKET SIZE, BY REGION, 2014–2021(USD MILLION)

Table 27 NORTH AMERICA COMBINATION ADJUVANTS MARKET SIZE, BY COUNTRY, 2014–2021(USD MILLION)

Table 28 EUROPE COMBINATION ADJUVANTS MARKET SIZE, BY COUNTRY, 2014–2021(USD MILLION)

Table 29 ASIA COMBINATION ADJUVANTS MARKET SIZE, BY COUNTRY, 2014–2021(USD MILLION)

Table 30 OTHER ADJUVANTS AND ITS DESCRIPTION

Table 31 OTHERS ADJUVANTS MARKET SIZE, BY REGION, 2014–2021(USD MILLION)

Table 32 NORTH AMERICA OTHERS VACCINE ADJUVANTS MARKET SIZE, BY COUNTRY, 2014–2021(USD MILLION)

Table 33 EUROPE OTHERS VACCINE ADJUVANTS MARKET SIZE, BY COUNTRY, 2014–2021(USD MILLION)

Table 34 ASIA OTHERS VACCINE ADJUVANTS MARKET SIZE, BY COUNTRY, 2014–2021(USD MILLION)

Table 35 VACCINE ADJUVANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2014–2021(USD MILLION)

Table 36 INTRAMUSCULAR ROUTE OF ADMINISTRATION MARKET SIZE, BY REGION, 2014–2021(USD MILLION)

Table 37 SUBCUTANEOUS ROUTE OF ADMINISTRATION MARKET SIZE, BY REGION, 2014–2021(USD MILLION)

Table 38 INTRANASAL ROUTE OF ADMINISTRATION MARKET SIZE, BY REGION, 2014–2021(USD MILLION)

Table 39 ORAL ROUTE OF ADMINISTRATION MARKET SIZE, BY REGION, 2014–2021(USD MILLION)

Table 40 INTRADERMAL ROUTE OF ADMINISTRATION MARKET SIZE, BY REGION, 2014–2021(USD MILLION)

Table 41 OTHERS ROUTE OF ADMINISTRATION MARKET SIZE, BY REGION, 2014–2021(USD MILLION)

Table 42 VACCINE ADJUVANTS MARKET SIZE, BY DISEASE TYPE,

2014–2021(USD MILLION)

Table 43 NEW CASES OF DISEASES (2014)

Table 44 INFECTIOUS DISEASES VACCINE ADJUVANTS MARKET SIZE, BY REGION, 2014–2021(USD MILLION)

Table 45 CANCER DISEASE VACCINE ADJUVANTS MARKET SIZE, BY REGION, 2014–2021(USD MILLION)

Table 46 OTHERS VACCINE ADJUVANTS MARKET SIZE, BY REGION, 2014–2021(USD MILLION)

Table 47 VACCINE ADJUVANTS MARKET SIZE, BY APPLICATION, 2014–2021(USD MILLION)

Table 48 VACCINE ADJUVANTS MARKET, BY RESEARCH APPLICATION, BY REGION, 2014–2021(USD MILLION)

Table 49 VACCINE ADJUVANTS MARKET, BY COMMERCIAL APPLICATION, BY REGION, 2014–2021(USD MILLION)

Table 50 VACCINE ADJUVANTS MARKET SIZE, BY APPLICATION CATEGORY, 2014–2021 (USD MILLION)

Table 51 LIST OF ADJUVANTS APPROVED FOR HUMAN USE BY FDA

Table 52 HUMAN VACCINE ADJUVANTS MARKET SIZE, BY REGION, 2014–2021 (USD MILLION)

Table 53 VETERINARY VACCINE ADJUVANTS MARKET SIZE, BY REGION, 2014–2021(USD MILLION)

Table 54 VACCINE ADJUVANTS MARKET SIZE, BY REGION, 2014–2021 (USD MILLION)

Table 55 NORTH AMERICA: VACCINE ADJUVANTS MARKET SIZE, BY COUNTRY, 2014–2021 (USD MILLION)

Table 56 EUROPE: VACCINE ADJUVANTS MARKET SIZE, BY COUNTRY, 2014–2021 (USD MILLION)

Table 57 ASIA: VACCINE ADJUVANTS MARKET SIZE, BY COUNTRY, 2014–2021 (USD MILLION)

Table 58 NORTH AMERICA: VACCINE ADJUVANTS MARKET SIZE, BY PRODUCT TYPE, 2014–2021 (USD MILLION)

Table 59 NORTH AMERICA: VACCINE ADJUVANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2014–2021 (USD MILLION)

Table 60 NORTH AMERICA: VACCINE ADJUVANTS MARKET SIZE, BY DISEASE TYPE, 2014–2021(USD MILLION)

Table 61 NORTH AMERICA: VACCINE ADJUVANTS MARKET SIZE, BY APPLICATION, 2014–2021(USD MILLION)

Table 62 NORTH AMERICA: VACCINE ADJUVANTS MARKET SIZE, BY APPLICATION CATEGORY, 2014–2021(USD MILLION)

Table 63 U.S.: VACCINE ADJUVANTS MARKET SIZE, BY PRODUCT TYPE, 2014–2021, (USD MILLION)

Table 64 CANADA: VACCINE ADJUVANTS MARKET SIZE, BY PRODUCT TYPE, 2014–2021(USD MILLION)

Table 65 EUROPE: VACCINE ADJUVANTS MARKET SIZE, BY PRODUCT TYPE, 2014–2021 (USD MILLION)

Table 66 EUROPE: VACCINE ADJUVANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2014–2021 (USD MILLION)

Table 67 EUROPE: VACCINE ADJUVANTS MARKET SIZE, BY DISEASE TYPE, 2014–2021(USD MILLION)

Table 68 EUROPE: VACCINE ADJUVANTS MARKET SIZE, BY APPLICATION, 2014–2021(USD MILLION)

Table 69 EUROPE: VACCINE ADJUVANTS MARKET SIZE, BY APPLICATION CATEGORY, 2014–2021 (USD MILLION)

Table 70 GERMANY: VACCINE ADJUVANTS MARKET SIZE, BY PRODUCT TYPE, 2014–2021 (USD MILLION)

Table 71 U.K.: VACCINE ADJUVANTS MARKET SIZE, BY PRODUCT TYPE, 2014–2021 (USD MILLION)

Table 72 FRANCE: VACCINE ADJUVANTS MARKET SIZE, BY PRODUCT TYPE, 2014–2021 (USD MILLION)

Table 73 REST OF EUROPE: VACCINE ADJUVANTS MARKET SIZE, BY PRODUCT TYPE, 2014–2021 (USD MILLION)

Table 74 ASIA: VACCINE ADJUVANTS MARKET SIZE, BY PRODUCT TYPE, 2014–2021 (USD MILLION)

Table 75 ASIA: VACCINE ADJUVANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2014–2021 (USD MILLION)

Table 76 ASIA: VACCINE ADJUVANTS MARKET SIZE, BY DISEASE TYPE, 2014–2021(USD MILLION)

Table 77 ASIA: VACCINE ADJUVANTS MARKET SIZE, BY APPLICATION, 2014–2021(USD MILLION)

Table 78 ASIA: VACCINE ADJUVANTS MARKET SIZE, BY APPLICATION CATEGORY, 2014–2021(USD MILLION)

Table 79 CHINA: VACCINE ADJUVANTS MARKET SIZE, BY PRODUCT TYPE, 2014–2021 (USD MILLION)

Table 80 INDIA: VACCINE ADJUVANTS MARKET SIZE, BY PRODUCT TYPE, 2014–2021 (USD MILLION)

Table 81 REST OF ASIA: VACCINE ADJUVANTS MARKET SIZE, BY PRODUCT TYPE, 2014–2021 (USD MILLION)

Table 82 REST OF THE WORLD: VACCINE ADJUVANTS MARKET SIZE, BY

PRODUCT TYPE, 2014–2021 (USD MILLION)

Table 83 REST OF THE WORLD: VACCINE ADJUVANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2014–2021 (USD MILLION)

Table 84 REST OF THE WORLD: VACCINE ADJUVANTS MARKET SIZE, BY DISEASE TYPE, 2014–2021(USD MILLION)

Table 85 REST OF THE WORLD: VACCINE ADJUVANTS MARKET SIZE, BY APPLICATION, 2014–2021(USD MILLION)

Table 86 REST OF THE WORLD: VACCINE ADJUVANTS MARKET SIZE, BY APPLICATION CATEGORY, 2014–2021(USD MILLION)

Table 87 AGREEMENTS & COLLABORATIONS, 2015

Table 88 ACQUISITIONS, 2015–2016

Table 89 EXPANSIONS, 2014

Table 90 OTHERS, 2014–2015

## List Of Figures

### LIST OF FIGURES

Figure 1 RESEARCH DESIGN

Figure 2 INCREASE IN AGING POPULATION, BY COUNTRY (2010 VS. 2015)

Figure 3 PERCENTAGE INCREASE IN AGING POPULATION, BY REGION  
(1980–2010 VS. 2010–2040)

Figure 4 GLOBAL BURDEN OF CANCER, BY REGION (2005–2030)

Figure 5 NUMBER OF NEW CANCER CASES BY COUNTRY

Figure 6 HEALTHCARE EXPENDITURE ACROSS MAJOR COUNTRIES, 2000 VS.  
2012

Figure 7 HEALTHCARE SPENDING MATRIX, BY COUNTRY (2013)

Figure 8 MARKET SIZE ESTIMATION: TOP-DOWN APPROACH

Figure 9 MARKET SIZE ESTIMATION: BOTTOM-UP APPROACH

Figure 10 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE,  
DESIGNATION, AND REGION

Figure 11 DATA TRIANGULATION METHODOLOGY

Figure 12 VACCINE ADJUVANTS MARKET SIZE, BY PRODUCT TYPE, 2016 VS.  
2021 (USD MILLION)

Figure 13 GLOBAL VACCINE ADJUVANTS MARKET SIZE, BY ROUTE OF  
ADMINISTRATION, 2016 VS. 2021 (USD MILLION)

Figure 14 GLOBAL VACCINE ADJUVANTS MARKET SIZE, BY DISEASE TYPE, 2016  
VS. 2021 (USD MILLION)

Figure 15 GLOBAL VACCINE ADJUVANTS MARKET SIZE, BY APPLICATION, 2016  
VS. 2021 (USD MILLION)

Figure 16 GLOBAL VACCINE ADJUVANTS MARKET SIZE, BY APPLICATION  
CATEGORY, 2016 VS. 2021 (USD MILLION)

Figure 17 GLOBAL VACCINE ADJUVANTS MARKET, BY REGION, 2016 (USD  
MILLION)

Figure 18 THE VACCINE ADJUVANTS MARKET IS EXPECTED TO SHOWCASE  
HIGH GROWTH OPPORTUNITIES DURING THE FORECAST PERIOD

Figure 19 THE RESEARCH APPLICATION SEGMENT IS EXPECTED TO ACCOUNT  
FOR THE LARGEST MARKET SHARE IN 2016

Figure 20 ASIAN COUNTRIES ARE EXPECTED TO WITNESS THE HIGHEST  
GROWTH RATE DURING THE FORECAST PERIOD

Figure 21 THE HUMAN VACCINE ADJUVANTS SEGMENT IS EXPECTED TO GROW  
AT THE HIGHEST CAGR DURING THE FORECAST PERIOD

Figure 22 THE INFECTIOUS DISEASE SEGMENT WILL CONTINUE TO DOMINATE

## THE MARKET IN 2021

Figure 23 ASIA IS EXPECTED TO WITNESS THE HIGHEST GROWTH RATE IN THE VACCINE ADJUVANTS MARKET DURING THE FORECAST PERIOD

Figure 24 THE PARTICULATE ADJUVANTS SEGMENT IS THE LARGEST SEGMENT OF THE VACCINE ADJUVANTS MARKET FROM 2016 TO 2021

Figure 25 THE INTRANASAL ROUTE OF ADMINISTRATION SEGMENT IS EXPECTED TO GROW AT THE HIGHEST CAGR DURING THE FORECAST PERIOD FROM 2016 TO 2021

Figure 26 THE CANCER DISEASE TYPE SEGMENT IS PROJECTED TO GROW AT THE HIGHEST CAGR DURING THE FORECAST PERIOD

Figure 27 CANCER INCIDENCE, BY REGION, 2012–2020

Figure 28 THE RESEARCH APPLICATION SEGMENT IS THE LARGEST IN THE VACCINE ADJUVANTS MARKET FROM 2016 TO 2021

Figure 29 HUMAN VACCINE ADJUVANTS ACCOUNTS FOR THE LARGEST SHARE IN VACCINE ADJUVANT MARKET, BY APPLICATION CATEGORY, IN 2016

Figure 30 ASIA IS EXPECTED TO WITNESS THE HIGHEST GROWTH IN THE VACCINE ADJUVANTS MARKET DURING THE FORECAST PERIOD

Figure 31 NORTH AMERICA: VACCINE ADJUVANTS MARKET SNAPSHOT

Figure 32 EUROPEAN VACCINE ADJUVANTS MARKET SNAPSHOT

Figure 33 ASIA: VACCINE ADJUVANTS MARKET SNAPSHOT

Figure 34 AGREEMENTS & COLLABORATIONS WAS THE KEY GROWTH STRATEGY FOR MARKET PLAYERS, 2013–2016

Figure 35 GLOBAL VACCINE ADJUVANTS MARKET SHARE ANALYSIS, BY KEY PLAYERS, 2015

Figure 36 BATTLE FOR MARKET SHARE: AGREEMENTS & COLLABORATIONS WAS THE KEY STRATEGY ADOPTED BY MARKET PLAYERS

Figure 37 PRODUCT BENCHMARKING FOR MAJOR PLAYERS

Figure 38 COMPANY SNAPSHOT: BRENNTAG AG

Figure 39 COMPANY SNAPSHOT: AIR LIQUIDE GROUP

Figure 40 COMPANY SNAPSHOT: CSL LIMITED

Figure 41 COMPANY SNAPSHOT: AGENUS, INC.

Figure 42 COMPANY SNAPSHOT: NOVAVAX, INC.

## I would like to order

Product name: Vaccine Adjuvants Market by Product Type (Particulate, Emulsions, Pathogen, Saponin), Route of Administration (Subcutaneous, Intramuscular), Disease Type (Infectious, Cancer), Application (Research, Commercial) & Application Category - Forecasts to 2021

Product link: <https://marketpublishers.com/r/V8A666B7FDBEN.html>

Price: US\$ 5,650.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/V8A666B7FDBEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below



and fax the completed form to +44 20 7900 3970